MG
SNDX icon

Marex Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Marex Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$552K Buy
25,260
+5,200
+26% +$108K ﹤0.01% 670
2026
Q1 		$469K Buy
20,060
+5,000
+33% +$109K ﹤0.01% 641
2025
Q4 		$316K Buy
+15,060
New +$263K ﹤0.01% 693

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Marex Group's SNDX Position: Q2 2026 in Review

Marex Group increased its Syndax Pharmaceuticals (SNDX) stake by 26% in Q2 2026, buying an estimated $108K and bringing the position to 25,260 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #670.

Marex Group first reported a position in SNDX in Q4 2025 and has held it in 3 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Marex Group held 25,260 shares of Syndax Pharmaceuticals worth $552K as of Q2 2026.
  • Marex Group bought 5,200 Syndax Pharmaceuticals shares in Q2 2026, an estimated $108K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #670 holding.
  • Marex Group first reported a position in Syndax Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.